Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Good DREAMM-1 Data Keeps GSK On Track For Multiple Myeloma Filing This Year

Executive Summary

Confirmation of good trial data for GSK's promising anti-BCMA antibody-drug conjugate GSK2857916 in multiple myeloma patients keeps it in the running for eventual regulatory approval by 2020 - but it faces a formidable field of emerging rival therapies.  

You may also be interested in...



Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

GSK Files Its BCMA Drug In Multiple Myeloma

GSK has filed its anti-BCMA agent with the FDA after full Phase II DREAMM-2 data showed an overall response rate of 31% in patients with heavily pre-treated multiple myeloma.

DREAMM-2 Put GSK’s BCMA Drug In Pole Position In Multiple Myeloma

The DREAMM-2 trial of the antibody-drug conjugate belantamab mafodotin in relapsed/refractory multiple myeloma patients has hit its primary endpoint, giving GSK a chance to file for approval before its BCMA rivals.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132082

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel